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Abstract
Background: galectin-1 has been implicated in tumor invasion and metastasis and is frequently over-expressed in
epithelial ovarian cancer (EOC), but its potential as a biomarker remains unclear. In this novel study, we have
explored the possible use of galectin-1 as a biomarker for EOC.
Methods: galectin-1 in sera was evaluated by ELISA in a pilot panel of EOC patients, healthy volunteers, patients
with benign gynecologic tumors or other gynecologic malignancies. We examined galectin-1 expression in EOC
tumor samples by Western Blot, qRT-PCR and immunohistochemistry. In vitro experiments were conducted to
elucidate the biologic role of galectin-1 in EOC progression using over-expression of galectin-1 in OVCAR-3 cells.
We also looked for the association of galectin-1 expression with clinic pathological variables and survival outcomes
in EOC.
Results: A significant difference was detected in serum galectin-1 between EOC patients with non-metastatic and
those with metastatic disease, but not between EOC patients and healthy volunteers. It increased in recurrent cases
and decreased after debulking surgery. Both of galectin-1 mRNA and protein levels were increased in 90 % of the
examined EOC tissue samples, compared with a wedge resection of a normal ovary. High galectin-1 in peritumor
stroma was primarily detected in advanced stages of EOC. Over expression of galectin-1 significantly increased the
ability of OVCAR-3 cells’ migration and invasion.
Conclusions: Our results suggest that galectin-1 might play a role in tumor progression and be associated with
poor outcome in EOC. It could be a novel prognostic and progression biomarker in EOC patients.
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Background
Ovarian cancer is the most common gynecological can-
cer and the leading cause of death from gynecological
malignancies in more developed areas, and the second
in less developed areas [1]. Approximately, 90 % of ovar-
ian cancer is histological classified as epithelial ovarian
cancer. The 5-year survival rate of most EOC patients is
only 20 to 30 % with the standard treatment of debulk-
ing surgery followed by paclitaxel and platinum (TP)
based chemotherapy [1, 2]. The most clinically useful
ovarian cancer biomarker, CA125, has been used to as-
sess response to treatment and monitor recurrence of
EOC [3], but unfortunately lacks both sensitivity and
specificity [4]. A significant proportion of epithelial ovar-
ian cancers do not express CA125, especially tumors of
clear cell, undifferentiated, and mucinous histological
subtypes [5]. In addition, multiple gynecological condi-
tions can lead to elevated CA125 levels, reducing its
overall specificity [6, 7]. There has therefore been a sig-
nificant interest in the identification and development of
new ovarian cancer markers and novel molecular
approaches.
Galectins constitute a gene family of widely distributed
carbohydrate-binding proteins characterized by their
affinity for β-galactoside-containing glycans. Currently
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there are 14 members in this family [8, 9]. galectin-1, a
14-kDa laminin-binding galectin, a member of the galec-
tin family of β-galactoside-binding proteins classified as
a proto-type galectin. It is a homodimer subunit posses-
sing two β-galactoside-binding sites [9, 10]. galectin-1
acts via both intracellular sugar-independent interactions
with other proteins, and extracellular sugar-dependent
autocrine or paracrine interactions with β-galactoside-
containing glycoconjugates [11]. Studies from several
groups suggest that galectin-1 may have a role in a var-
iety of physiological and pathological processes including
cell-cell and cell-matrix interactions, cell growth, inflam-
matory reaction and immune regulation [11–13]. Of
most relevance to the present study are experimental
observations to link the dysregulation of galectin-1
expression to the invasion and metastasis formation of
cancer cells [14, 15], promote tumor angiogenesis [12, 16]
and protect tumors from host immune responses [17, 18].
In most cases, galectin-1 is up-regulated in cancer cells as
reported in thyroid carcinoma by Chiariotti [19] and by
Xu [20]. Similarly, increased galectin-1 expression has
been correlated with the metastatic potential of several
tumorigenic cells, possibly by affecting cell motility and
invasion of extracellular matrices [15, 21–23]. It is also de-
tected in neighboring cancer associated fibroblasts [CAFs
express α-smooth muscle actin (α-SMA), which can be as
a CAF marker] and cancer stroma as reported in the pri-
mary prostate cancer by Van den Brule and Berberat PO
[24, 25]. Moreover, galectin-1 accumulation in the peri-
tumoral stroma of breast cancer and ovarian cancer
regulates both cancer cell proliferation and invasiveness
[26, 27]. Recently, it has been shown that galectin-1 is
strongly expressed in ovarian cancer and promotes pro-
gression and chemoresistance to cisplatin in epithelial
ovarian cancer [28, 29]. But its potential as prognostic,
diagnostic, or detection marker remains unclear.
In this report, we showed that galectin-1 was able to
be released from ovarian cancer cells and cancer associ-
ated fibroblasts. The released galectin-1 can be detected
in the conditioned culture media of EOC and CAF cells
expressing galectin-1, as well as in the peripheral circu-
lation of a majority of EOC patients. Because the expres-
sion levels of mRNA and protein galectin-1 were
increased in ovary carcinoma samples, compared with
normal ovary tissue by western blot and qRT-PCR, the
clinic pathologic significance of galectin-1 was further
evaluated using IHC of paraffin-embedded archival tis-
sue specimens and statistical analysis. In vitro experi-
ments were performed to determine the function of
galectin-1 in cell survival, proliferation, and invasion and
migration using over expression of galectin-1 in
OVCAR-3 cells. Our findings provide substantial evi-
dence that galectin-1 is a potential biomarker for the
prognosis and progression of EOC, but not a screening
tool, and their dysregulation might play an important
role in the progression of EOC.
Methods
Patients
The patients and healthy individuals signed an informed
consent form for the study which was reviewed by the
Institutional Review Board. All tissue samples were veri-
fied by histopathology. A group of formalin-fixed and
paraffin embedded archival tissue specimens including
110 cases of primary EOC and 50 cases of normal ovary
tissue were used for IHC. Patients were identified from a
database containing clinic pathological and follow-up
data of all EOC treated with primary debulking surgery
followed by TP based chemotherapy according to stand-
ard treatment protocols by gynecological oncologists in
the Hunan Cancer Hospital (Changsha, China) between
2008 and 2012. Surgical evaluation was used to deter-
mine the clinical stage and presence of metastases,
whereas histo-pathologic analysis was performed by gy-
necologic pathologists to assess cancer type and grade.
The clinic-pathologic features of the patients used in the
present study are shown in Table 3. Seventy patients
were serous carcinoma, 25 were mucinous carcinoma,
ten were endometriod carcinoma, and five were clear
cell carcinoma. All patients were staged according to the
2014 FIGO classification. Follow-up of all patients was
performed regularly up to 5 years with gradually increas-
ing intervals. Fifty patients developed tumor recurrence
during the postoperative follow-up periods. Among
them 40 patients developed pelvic or abdominal metas-
tasis. Ten patients developed pulmonary metastasis, and
20 patients developed lymphatic metastasis. Twenty of
them died of the metastatic disease.
Sera
Blood samples were obtained from patients being seen
in the Hunan Cancer Hospital. A total of 140 patients
with histological proven diagnosis of primary EOC were
included in this study. Samples were allowed to clot,
and the serum was stored at −80 °C until assayed. In
ten patients, galectin-1 serum levels were measured be-
fore and after resection of the primary tumor. Samples
were also obtained from 70 normal female blood do-
nors and 40 patients with benign gynecologic tumors
from Hunan Province in China (median age of 45 years;
range: 21–65 years).
Tissue samples and construction of tissue microarrays
(TMA)
Briefly, primary tumor samples were arrayed using a tis-
sue microarrayer (Beecher Instruments, Silver Spring,
Maryland) by taking four representative cores with a
diameter of 0.6 mm from marked tumor sites from the
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individual paraffin embedded tumor block onto a recipi-
ent paraffin block at pre-defined array locations. For
staining, 4 μm sections were cut from each TMA block
and applied to APES-coated slides. H&E staining was
performed to verify the presence of tumor in the arrayed
samples.
Immunohistochemical staining (IHC)
TMA sections were dewaxed and rehydrated, where-
upon antigen retrieval was performed in a citrate buffer
(pH 6.0). Endogenous peroxidase activity was blocked by
a 3 % H2O2 solution, after which sections were incu-
bated overnight at 4 °C with the primary antibody dilu-
tion: anti-galectin-1 (Santa Cruz, CA, USA). Sections
were subsequently incubated with DAKO Envision
+ (Dako, Heverlee, Belgium). Antigen-antibody reactions
were visualized with 3, 3-diaminobenzidine, the chromo-
genic substrate for peroxidase, and hematoxylin was
used to counter stain the tissue. To evaluate galectin-1
expression, each case was rated according to a score that
added a scale of intensity of staining to the area of stain-
ing. At least ten high-power fields were chosen ran-
domly, and >1,000 cells were counted for each section.
The intensity of staining was graded on the following
scale: 0, no staining; 1+, mild staining; 2+, moderate
staining; 3+, intense staining. The area of staining was
evaluated as follows: 0, no staining of cells in any micro-
scopic fields; 1+, <30 % of tissue stained positive; 2+,
between 30 % and 60 % stained positive; 3+, >60 %
stained positive. The minimum score when summed (ex-
tension + intensity) was therefore, 0, and the maximum, 6.
A combined staining score (extension + intensity) of ≤2
was considered to be a negative staining; a score of three
was considered to be a weak staining; whereas a score be-
tween 4 and 6 was considered to be a strong staining.
Human EOC cell lines culture
The human EOC cell lines SKOV3 and OVCAR-3 were
purchased from American Type Culture Collection
(ATCC, USA). All cell lines were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10 % fetal bovine serum and antibiotics in a hu-
midified atmosphere of 95 % air and 5 % CO2 at 37 °C.
Human cancer associated fibroblast (CAF) cells culture
After several washings with sterile phosphate-buffered
saline (PBS), a 2–3 cm2 piece of tumor tissue from EOC
patients was minced into smooth paste with scissors and
incubated on an orbital shaker with 10 ml of PBS and
10 ml of 0.25 % trypsin/25 mM EDTA at 37 °C for about
2 h. The solution containing cells in suspension was fil-
tered by a nylon mesh with 40um micron pores and
then centrifuged at 1500 r.p.m. for 5 min. The pellet was
plated with 20 ml of RPMI 1640, with 20 % FBS and
penicillin/treptomycin and incubated at 37 °C and the
medium was exchanged after 48 h for the first time and
every third day thereafter.
Production of the vector expressing galectin-1 and
transduction of target cells
The galectin-1 sequences were amplified by PCR, con-
firmed by sequencing, and then inserted into a pIRES2-
ZsGreen1 vector to generate pIRES2-ZsGreen1-galectin-1.
OVCAR-3 cells were transfected with pIRES2-ZsGreen1-
galectin-1 using LipofectamineTM 2000 kit (Invitrogen) to
produce polyclonal cells with stable expression of
galectin-1 and confirmed by western blotting.
Immunocytochemical (ICC)
For immunocytochemical, the CAFs were plated on steril-
ized coverslips in six-well plates and cultured for 24 h.
until the cells adhered, the medium was discarded and the
slides harvested for ICC staining. The slides were blocked
with 3 % H2O2 for 15 min and 10 % normal goat serum
for 15 min at room temperature. Then the slides were in-
cubated withα-SMA (Bioworld Technology, Minion, USA)
and galectin-1 ((Santa Cruz, CA, USA) primary antibodies
at 4 °C overnight. The HRP-conjugated secondary anti-
body (Tiangen Biotech, Beijing, China) and 3′-diamino-
benzidine tetrahydrochloride were used to visualize signal
development, and then the sections were counterstained
with hematoxylin. All the sections were observed and
photographed with an Axioskop 2 microscope (Carl Zeiss,
Oberkochen, Germany).
Preparation of cell lysate and the conditioned culture
media
Whole cell lysates were prepared by adding lysis buffer
(62.5 mM Tris–HCl (pH 6.8), 10 % glycerol, 2 % SDS) to
80 % confluent cell cultures. Protein concentration was
determined using the BCA assay kit (Pierce, Rockford,
IL). For the preparation of the conditioned culture
media, cells were grown to 80 % confluence and then
with FBS free media for 24 h. The conditioned culture
media were collected and centrifuged at 1,000 rpm for
10 min to remove cells and debris, and were further
concentrated by Centriplus YM-10 (Millipore).
ELISA assay for galectin-1
A non-extraction GALECTIN-1 enzyme-linked immuno-
sorbent (ELISA) kit from Kangchen Bio-tech (Shanghai,
China) was used for determination of galectin-1 level in
sera, cell lystae and cell culture media. Samples were con-
centrated by Centriplus YM-10 (Millipore) and contested
in triplicates and repeated if the correlation coefficient be-
tween the absorbance and the amount in the standards
was less than 0.95. Long-term storage (≤6 months) of
frozen serum or 1 week of storage at 4 °C did not
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significantly alter galectin-1 content. No difference in
galectin-1 measurements was observed after two freeze-
thaw cycles.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted with the Trizol Kit (Invitrogen,
USA) according to the manufacturer’s instructions.
QRT-PCR was performed using a SYBR® Green Realtime
PCR Master Mix kit (TOYOBO, Japan) as the manufac-
turer’s instructions. The primer sequences used were as
follows: galectin-1 forward primer 5′-CCGGGGGCCCA
TCTCTCTCG-3′, reverse primer 5′–CTGGCGAC CA
GACCACAAGCC-3′. GAPDH forward primer 5′-TGC
ACCACCAACTGCTTAGC-3′, reverse primer 5′- GG
CATGGACTGTGGTCATGAG −3′. All experiments
were repeated at least three times.
Co-immunoprecipitation and western blotting
The supernatant from whole cell lysates was harvested
and immunoprecipitated using the primary antibodies or
non-specific IgG as a negative control, which was pre-
cleared by protein G magnetic beads at 4 °C overnight.
Proteins were separated on 10 or 12 % SDS-PAGE gels
and transferred onto nitrocellulose membranes (Bio-
Rad, Hercules, CA, USA). About 50 μg of protein ex-
tracts of ovary tissues were run on one-dimensional gel
and the separated proteins were electro transferred onto
nitrocellulose paper and incubated with blocking buffer.
Individual membranes were washed and incubated with
anti-galectin-1 mouse monoclonal antibody (Santa Cruz,
CA, USA), anti-CA125 mouse monoclonal antibody
(Santa Cruz, CA, USA) or mouse anti-β-actin antibody
(Kangchen Bio-tech Shanghai, China) overnight at room
temperature. After the following secondary antibody in-
cubation, the membranes were visualized with chromo-
gens of BCIP (5-bromo-4-chloro −3-indolyl phosphate)
and NBT (nitro-bluetetrazoline). All experiments were
repeated at least three times.
In vitro cell growth, proliferation assay, apoptosis assays
The effect of the test agents on cell viability was assessed
with the MTT assay. Apoptosis was assessed using an
Annexin V-coupled fluorescein isothiocyanate (FITC)
apoptosis detection kit (BD Pharmingen, San Diego, CA,
USA). Briefly, OVCAR-3/ pIRES2-ZsGreen1 -galectin-1
and OVCAR-3/ pIRES2-ZsGreen1 control cells were re-
moved from a six-well plate by incubation with trypsin-
EDTA, washed twice in PBS, and re-suspended in 1 ml
of Annexin V-binding buffer at 106cells/ml. Annexin V-
coupled FITC and propidium iodide were added (each at
5 μl per 105 cells). Samples were mixed gently, incubated
for 15 min at room temperature in the dark, and then
subjected to flow cytometry to evaluate the number of
apoptotic cells. All experiments were repeated at least
three times.
Transwell migration and invasion assay
In vitro invasion assay was performed in a transwell sys-
tem (Corning, Corning, USA). Briefly, Matrigel was
added to the upper surface of a polycarbonic membrane
(pore size 8 μm) to form a thin gel layer, which served
as the ECM. The filter was dried in a laminar hood
overnight, and then reconstituted with 100 μl of PBS at
37 °C for 2 h. The upper compartment of the filter con-
tained the treated cells at a density of 2 × 105 cells/well
in 100 μl of SFM. The bottom filter was filled with
600 μl of conditional medium . After 24 h incubation at
37 °C with 5 % CO2, the polycarbonic membrane was
fixed with 100 % methanol for 10 min and stained with
0.2 % crystal violet solution, then the cells on the upper
surface were completely removed by wiping with a cot-
ton swab. Cells that had penetrated to the lower surface
of the filter were counted under an Olympus microscope
in three randomized fields at a magnification of 200×.
Cell migration assay was carried out in a transwell filter
on membrane filters not coated with Matrigel. Migration
of cells transduced with pIRES2-ZsGreen1-galectin-1 or
pIRES2- ZsGreen1 -control was measured as described
in the invasion assay. Each assay was performed at least
three times.
Statistical analyses
All quantitative data are presented as the mean ± SD.
SPSS version13.0 was used for statistical analysis.
Methods to analyze the statistical significance of differ-
ences were student’s two-tailed t-test in two groups and
one-way ANOVA in multiple groups. Pearson’s chi-
square test and Fisher’s exact test were used to assess
the statistical significance of the association between
galectin-1 expression and clinic pathologic parameters.
P < 0.05 was considered statistically significant.
Results
Serum galectin-1 from normal controls and patients with
EOC cancer
The levels of galectin-1 in sera of 70 healthy controls
varied between 30 and 231 ng/ml (median, 88 ng/ml;
95th percentile, 174.3 ng/ml; Table 1). The 95th per-
centile of galectin-1 levels (174.3 ng/ml) was arbitrarily
taken as the upper limit of normal. There was no sig-
nificant difference between serum galectin-1 levels and
age, menopausal status or blood type. Serum galectin-1
concentrations of healthy individuals and patients with
EOC are summarized in Table 1. Five (11 %) of the 45
patients with local disease (stageI) and 47 (50 %) of the
95 patients with metastatic EOC (stageII-IV) showed
serum galectin-1 levels above the upper limit of normal.
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As a whole, there was no a significant difference be-
tween healthy individuals, benign gynecologic tumor
patients and patients with EOC. There was no a signifi-
cant difference between different types of ovarian
tumor histologies. However, a significant difference in
serum galectin-1 was seen between EOC patients with
non-metastatic and those with metastatic disease (P =
0.034). Furthermore, a significant difference in serum
galectin-1 was also observed between EOC patients
with different FIGO stage (P = 0.041). In 140 patients
with early-stage or late-stage EOC, the median
galectin-1 concentration in serum was 139 ng/ml
(range, 30–950 ng/ml). Serum galectin-1 levels in 10
EOC patients were measured before and 2 days after
primary debulking surgery. In nine of these cases, there
was a decrease in the galectin-1 serum concentrations
after surgery (Fig. 1a). One patient with pelvic lymph
node involvement had a preoperative galectin-1 serum
level of 595 ng/ml that dropped to165 ng/ml within
2 days after satisfied surgery. In contrast, in one patient
with localized tumor with normal galectin-1 serum
level before surgery, no significant change was observed
in galectin-1 serum concentration. Interestingly, serum
concentrations of galectin-1 increased in 7/10 recurrent
cases compared with the level at the end of treatment
(Fig. 1b).
Comparison of galectin-1 and CA125 levels
CA125 is the most clinically useful ovarian cancer bio-
marker. We therefore wished to compare the galectin-1
positivity with CA125 values in our tumor panel. EOC
patients that demonstrated high levels of CA125 also
tended to exhibit high levels of galectin-1 (Fig. 1c). At a
CA125 threshold of 35 U/ml, fifteen of CA125-negative
plasma samples were in galectin-1-positive range. 98 of
the 140 cancer patients identified as positive by CA125
were also positive using galectin-1 and 22 patients were
negative for both (Table 2). Using Fisher’s exact test, the
association between galectin-1 and CA125 positivity was
shown to be highly significant (P = 0.001), confirming the
lack of independence between these two markers. A false
positive obtained with CA125 was negative obtained by
galectin-1. Interestingly, using co-immunoprecipitation
we found that the protein of galectin-1 combined with
CA125 in galectin-1- pIRES2-ZsGreen1 transfected
OVCAR-3 cells (Fig. 1d). It has been also implicated that
CA125 represents a novel counter receptor for galectin-1
in Hela cells [30].
Cancer cells and cancer associated fibroblasts (CAF) in
culture release galectin-1 proteins
In order to test the possibility that galectin-1 may be re-
leased from cancer cells and CAF, we looked for the
Table 1 Levels of galectin-1 in the sera of EOC patients and healthy controls
galectin-1 (ng/ml)
Diagnosis No. of patients Median 5th percentile 95th percentile Range P
Healthy donors 70 88 30 174.3 30–231 0.15a
Benign Gyn Tumor 60 78 32.5 169.8 30–229 0.38b
Other Gyn
Malignancies 50 92 33.5 176.5 30–240 0.042c
Histologies
Serous 105 191 31.5 760
Mucinous 45 202 34.5 812
Endometroid 37 179 29.8 745
Clear cell 23 182 30.2 789 0.784d
EOC 140 149 34.5 828 30–950
Nonmetastatic 45 69 36.2 169.3 30–163
Metastatic 95 370 40 840 30–950 0.034e
EOC stage
I 44 69 36.2 169.3 30–163
II 35 260 39 370 30–390
III 46 352 180 590 170–610
IV 15 630 505 890 480–950 0.041f
a-f Ps refers to the difference between the cohorts of healthy individuals and EOC patients a, or the difference of EOC patients and patients with benign
gynecologic tumors b, or the difference of EOC patients and patients with other gynecologic malignancies c, or between the groups of EOC patients with
different histology d, or the difference between the groups of patients with nonmetastatic and metastatic disease e or the groups of patients with stageI- IVf.
EOC epithelial ovarian cancer, Gyn gynecologic
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presence of galectin-1 in conditioned culture media from
EOC cell lines and CAF cells. A primary cell line of CAF
expressing galectin-1 (Fig. 2a) was cultured from an
EOC patient and confirmed by ICC using anti-α-SMA
(Fig. 2b). Conditioned culture media from OVCAR-3,
SKOV3 and CAF cells were collected and concentrated.
ELISA was performed to detect galectin-1 in the condi-
tioned culture media (Fig. 2c). Interestingly, the presence
of galectin-1 in the media corresponded to expression of
galectin-1 in the various cell lines. galectin-1 was not
detected in the media of OVCAR-3 lacking galectin-1
expression. However, glectin-1- pIRES2-ZsGreen1 trans-
fected OVCAR-3 cells showed high levels of galectin-1
both in the media and the lysate. Overall, our findings
show that, when expressed in a cell, a fraction of the
galectin-1 protein can be released in the media. Both
EOC cells and CAF cells are able to release galectin-1 in
the media.
galectin-1 is involved in EOC cell migration and invasion
in vitro
To elucidate the role of galectin-1 in EOC progression,
pIRES2-ZsGreen1 vector was used to increase galectin-1
expression in OVCAR-3 cells which have no galectin-1
protein expression (Fig. 2d). Up-regulation of galectin-1
expression was observed in galectin-1-pIRES2-ZsGreen1
transfected OVCAR-3 cells (relative to the GFP control)
(Fig. 2e). galectin-1 up-regulation significantly increased
migration and invasion abilities of OVCAR-3 cells com-
pared with the GFP control (P < 0.01) (Fig. 2f–g). How-
ever, no effect was observed in proliferation and
apoptosis for OVCAR-3 cells (data not showed).
Identification of high galectin-1 expression in EOC tumor
specimens and statistical analysis
Western blotting and qRT-PCR were done to detect the
expression levels of galectin-1 in cancerous ovary tissue
from 36 EOC patients compared with a wedge resection
of 32 normal ovaries. As shown in Fig. 3a, b and c,
galectin-1 was significantly up-regulated in both mRNA
and protein levels (P < 0.05) in 32 (90 %) of EOC pa-
tients. Because of its cell type specificity, IHC was con-
sidered as the most reliable detection technique,
allowing discrimination between normal and neoplastic
Table 2 CA125 and galectin-1 in EOC plasma samples
galectin-1+ galectin-1−
CA125 positive 98 5
CA125 negative 15 22
EOC epithelial ovarian cancer
Fig. 1 The changes of galectin-1 levels and its relationship with CA125 in the plasma of EOC patients. a Serum galectin-1 concentrations in 10
patients with EOC before (Pre-) and 2 days after (Post-) primary debulking surgery. b Serum galectin-1 levels before (Pre) and at recurrence (At-)
in 10 EOC patients. c CA125 levels in plasma of 140 EOC patients are compared to galectin-1 expression levels. d Co-immunoprecipitation of
CA125 and galectin-1 in galectin-1- pIRES2 - ZsGreen1 transfected OVCAR-3 cells. EOC: epithelial ovarian cancer; NC: negative control; Co-IP:
co-immunoprecipitation. *P < 0.05
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tissue. After showing the increased expression of
galectin-1 in epithelial ovarian cancerous tissue com-
pared to the normal ovarian tissue by western blot and
qRT-PCR analysis, we investigated the level of galectin-1
expression in the pathologic specimen of EOC patients
using the IHC method. galectin-1 expression was hetero-
geneous from sample to sample.
Levels of galectin-1 expression in cancer cells
galectin-1 was stained both in cancer cells with a cyto-
plasmic pattern and in stromal cells (Fig. 3d). The levels
of galectin-1 expression in cancer cells were analyzed to
the pathologic and clinical information (Table 3). The
levels of galectin-1 expression did not show any
statistically significant changes according to tumor stage,
tumor invasiveness, presence of lymph node metastasis.
Levels of galectin-1 expression in cancer-associated
stromal (CAS) cells
Examination of the stroma associated with the carcin-
oma cells demonstrated that it was positive for galectin-
1 immunostaining in a large majority of samples (score
3–6 in 81 of 110 cases). However, the stroma associated
with the normal tissue, when present on the slide, was
characterized by low or absent immunostaining (score
0–3 in 46 of 50 cases). The levels of galectin-1 expres-
sion in CAS cells of epithelial ovarian cancer tissues
varied among patients. In contrast to the results of
Fig. 2 Expression of galectin-1 in various EOC cell lines and in vitro invasion and migration assays using pIRES2-ZsGreen1-galectin-1 transduced
OVCAR-3 cells. a–b The basal expression of galectin-1 (a, ×40) determined by ICC in CAF cells confirmed by α-SMA staining (b, ×40). c ELISA
detected galectin-1 in conditioned culture media of SKOV3 cells, OVCAR-3 cells, galectin-1- pIRES2 - ZsGreen1 transfected OVCAR-3 cells and CAF
cells. d Basal expression of galectin-1 in ovarian cancer cell lines. e The expression of galectin-1 was increased by transfecting OVCAR-3 cells with
pIRES2-ZsGreen1-galectin-1. 1 represents OVCAR-3 alone; 2 represents pIRES2-ZsGreen1 transfected OVCAR-3 cells; 3 represents pIRES2-ZsGreen1-
galectin-1 transfected OVCAR-3 cells. f–g Up-regulation of galectin-1 by pIRES2-ZsGreen1-galectin-1 increased the capacity of invasion (f) and
migration (g) for OVCAR-3 cells. NC: Negative control; EOC: epithelial ovarian cancer; galectin-1:galectin-1; CAF: cancer associated fibroblast;
IHC: Immunohistochemistry. **P < 0.01
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galectin-1 staining in the cancer cell, statistical analysis
of the data revealed the staining results of the stromal
cells showed significant correlation with pathologic vari-
ables of the EOC patients (Table 3). High levels of
galectin-1 expression in stromal cells were observed in
the invasive carcinoma compared to the non-invasive
carcinoma (p = 0.004), and the levels of galectin-1 ex-
pression in CAS cells showed positive correlation with
FIGO stages of EOC. The stromal galectin-1 expression
were significantly higher in patients with lymph node
metastasis (p = 0.041). Interestingly, when EOC patients
were divided into two groups according to staining in-
tensity of immunohistochemistry, namely a weak expres-
sion group (score = 0–3) and a strong expression group
(score = 4–6), the recurrent rate in 3 years was higher in
the strong galectin-1 expression group than that in the
weak galectin-1 expression group (P = 0.002) (Table 3).
Discussion
There has been a sustained interest in the identification
of bio-markers for the prognosis and progression of
EOC since quite a few epithelial ovarian cancers are
CA125 negative and it is not very specific or sensitive.
Additional EOC serum markers will be required to iden-
tified for all patients in an initial phase of screening as
20 % of ovarian cancers have little or no expression of
CA125 [4]. More than 30 serum markers have been eval-
uated alone and in combination with CA125 by different
Fig. 3 Representative results of galectin-1 expression in the tissue specimens. a QRT-PCR shows changes in the expression levels of galectin-1 in
EOC cancerous tissue and normal ovary sample. b Western blotting shows changes in the expression levels of galectin-1 in EOC cancerous
tissue and normal ovary samples. c Histogram of relative changes in the expression level of galectin-1 protein in the tumor and normal tissues
as determined by densitometric analysis. d The typical examples of galectin-1 expression in human EOC determined by immunohistochemistry:
(a) Negative galectin-1 expression in normal ovary tissue (×200). b, c Strong galectin-1 expression in EOC cells and cancer-associated stroma [×200 for
(b) and ×400 for (c)]. d, e Negative galectin-1 expression in cancer cells but strong galectin-1 expression in cancer associated stroma [×200 for (d) and
×400 for (e)]. *P < 0.05. EOC: epithelial ovarian cancer; galectin-1:galectin-1; E: EOC cancerous tissue; N: normal ovary sample; NC: Negative control
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investigators, such as Kallikreins, osteopontin, leptin,
HE-4, LPA, MUC1 and SLP I [31–35] can improve the
predictive value in the past several years through various
approaches, including gene expression profiling and pro-
teomics analysis of ovarian tumors. But the usefulness of
these markers alone or in various combinations still re-
mains to be determined [36]. galectin-1 has emerged as
a protein commonly elevated in ovarian cancer [28, 29].
Here, our study demonstrates that galectin-1 expression
is increased in EOC patients, preferentially in sera and
in the adjacent peritumoral stroma. We have measured
serum galectin-1 concentrations in 140 patients with
EOC. Compared with the levels in 70 healthy individ-
uals, only about 37 % of examined EOC cases showed
galectin-1 concentration more than the cutoff level;
however, the incidence of supernormal levels of galectin-
1 was elevated in relation to tumor progression. Serum
galectin-1 levels were significantly higher in patients
with metastatic disease compared with patients with lo-
calized tumors. This tendency, that the increase in
serum galectin-1 levels was associated with the occur-
rence of metastasis. Our results could imply that the
metastatic spread of malignant tumors involves a higher
level of galectin-1 in the circulation. We are proposing
that increasing the serum level of galectin-1 may favor
metastasis by the following-mentioned modalities: (a)
enhancing the adhesive interactions between tumor cells
and the extracellular matrix proteins, such as laminin, fi-
bronectin, and vitronectin [37]; (b) promoting tumor cell
embolization through increased cell adhesion and dis-
semination of tumor cells in the circulation [38, 39]; (c)
elevating tumor vascular permeability [40]; and (d) con-
ferring a selective survival advantage to metastatic cells
(anoikis) [19, 41, 42]. Alternatively, galectin-1 serum
levels may reflect an immune reaction to the tumor load
from inflammatory cells that are known to express
galectin-1. However, this seems unlikely because we
found no correlation between the extent of the inflam-
matory response in operable EOC and further disease
progression. The source of increased serum galectin-1 in
cancer patients remains unclear. According to our re-
sults, that removal of the tumor decreased serum
galectin-1 concentrations, tumor tissues are likely to
produce and secrete galectin-1 in sera. However, immu-
nostaining of cancerous tissue showed that galectin-1
was expressed not only on malignant cells but also in
Table 3 galectin-1 expression in cancer cells and cancer-associated stromal cells along various pathologic characteristics
Tumor pathology Staining location Levels of expression Total p value
Weak (0, 3+) Strong (4+, 6+)
FIGO stage CASa
I 15 (76.0 %) 5 (24.0 %) 20 0.020
II 12 (43.0 %) 17 (57.0 %) 29
III 12 (32.0 %) 25 (68.0 %) 37
IV 3 (12.4 %) 21 (87.6 %) 24
EOCbcells
I 7 (36.5 %) 13 (63.5 %) 20 0.478
II 4 (14.4 %) 25 (85.6 %) 29
III 8 (21.5 %) 29 (78.5 %) 37
IV 8 (35.5 %) 16 (64.5 %) 24
Lymph CASa
node metastasis Metastasis (−) 32 (48.2 %) 35 (51.8 %) 67 0.041
Metastasis (+) 12 (28.5 %) 31 (71.5 %) 43
EOCbcells
Metastasis (−) 14 (21.6 %) 53 (78.4 %) 67 0.214
Metastasis (+) 14 (32.8 %) 29 (67.2 %) 43
Recurrence CASa
Recurrence (−) 46 (77.3 %) 14 (22.7 %) 60 0.002
Recurrence (+) 15 (30.8 %) 35 (69.2 %) 50
EOCbcells
Recurrence (−) 24 (39.5 %) 36 (60.5 %) 60 0.245
Recurrence (+) 13 (25.6 %) 37 (74.4 %) 50
aCancer-associated stromal. bEpithelial ovarian cancer
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stromal cells (mainly fibroblasts) near cancer nests, and
the stromal cells immediately adjacent to cancer nests
have a higher galectin-1 expression in comparison to
those cells farther away from the nests. Both EOC cells
and CAF released galectin-1 in the conditioned culture
media. These results suggest that circulating galectin-1
is generated not only by tumor cells but also from peri-
tumoral stromal cells.
In addition, we performed both qRT-PCR and western
blot to demonstrate high expression of galectin-1 in EOC
tumor specimens. The clinic pathologic significance of
galectin-1 was further evaluated using immunohistochem-
istry of paraffin-embedded archival tissue specimens and
statistical analysis. The expression pattern of the galectin-
1accumulation in the stroma has also been reported sur-
rounding thyroid [19], colon [43, 44], gliomas [22], pros-
tate carcinoma [24] and beast cancer [27]. Our report
demonstrates that high galectin-1 expression in cancer-
associated stroma correlates with various clinic pathologic
parameters, such as tumor invasiveness, advanced
stage, metastasis and higher recurrent rate. Van den
Bru le et al. [24, 26] observed the expression of
galectin-1 mRNA in peritumoral fibroblasts close to
ovarian carcinoma cells in human ovarian carcinoma
tissues, and demonstrated the galectin-1 secretion from
the activated fibroblast cell line. Moreover, the con-
ditioned media from certain ovarian cell lines were
shown to modulate the galectin-1 expression in fibro-
blasts regardless of galectin-1 expression status in pri-
mary cell lines. Berberat et al. [25] also reported that
galectin-1 mRNA expression in stromal fibroblasts by
in situ hybridization in pancreatic cancer. Two possible
mechanisms may explain this. Firstly, galectin-1-
expressing carcinoma cells can synthesize and secrete
galectin-1into stromal cells using its non-classical
secretory pathway [45]. Secondly, galectin-1 can be syn-
thesized by stromal cells, especially stromal fibroblasts,
as they get stimulated by oncologic signals from carcin-
oma cells or from ECM during ECM remodeling.
Therefore, at least in part the galectin-1 expression in
cancer-associated stromal tissue is due to the synthesis
in stromal fibroblasts, and this stromal galectin-1 ex-
pression can be modulated by conditions of tumor
microenvironment. Although it is not yet fully eluci-
dated, the role of galectin-1 in cancer-associated stroma
is certainly an interesting issue due to the highlighted
significance of tumor-stromal interactions [46, 47]. In
vitro experiments, we showed that over expression of
galectin-1 in OVCAR-3 cells significantly increased the
ability of cells’ migration and invasion.
Conclusions
Our study demonstrates the increased galectin-1 expres-
sion in EOC and stresses the clinical significance of
galectin-1 expression in sera and cancer-associated
stroma, a finding that could be important for cancer
progression. When taken together with galectin-1’s role
in cancer cells migration and invasion, we believe that
galectin-1 can be a key player in tumor stroma inter-
action in EOC, and the detection of increased galectin-1
levels in the serum of certain patients with cancer may
reflect biological aspects of tumor behavior associated
with a metastasizing phenotype. More studies are war-
ranted to determine the clinical value of circulating
galectin-1 in patients with early-stage cancer as a pre-
dictor of tumor invasion and metastasis. The influence
of host-derived versus cancer cell–derived galectin-1 on
cancer progression remains to be further elucidated.
These data support a role for galectin-1 to be a novel
prognostic and progression biomarker in EOC patients.
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